The specific pharmacological effect cannot be determined from the above information

By binding to FK binding protein-12 (FKBP-12) to form an immunosuppressive complex, it inhibits mTOR activity and blocks cytokine-driven T cell proliferation (development from G1 phase to S phase). It can prolong the survival of allogeneic transplants in various animal models, reverse acute rejection reactions, and produce immune tolerance to allogeneic antigens in some cases. It also inhibits immune-mediated reactions in various autoimmune diseases, such as systemic lupus erythematosus and collagen-induced arthritis.

Suppresses immune system function

In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. It also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.